Clinical Trials Logo

Nasopharyngeal Neoplasms clinical trials

View clinical trials related to Nasopharyngeal Neoplasms.

Filter by:

NCT ID: NCT01604564 Completed - Clinical trials for Adenomatous Polyposis Coli

Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients

KOPOF
Start date: May 2012
Phase:
Study type: Observational

The purpose of this registry is to collect information about patients in which a pouch has been created to improve in the future the quality of the surgery of the pouch.

NCT ID: NCT01596868 Completed - Clinical trials for Toxicity Due to Radiotherapy

GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China

Start date: May 2012
Phase: Phase 2
Study type: Interventional

The present study is a randomized, control, phase II study of locally advanced nasopharyngeal carcinoma (NPC) in Northwest China treated with Gemcitabine plus cisplatin regimen (GP) or Docetaxel plus cisplatin regimen (TP) induction chemotherapy followed by concurrent chemoradiotherapy. The population consists of stage III-IVb nasopharyngeal carcinoma (NPC). The effectiveness, side effects and quality of life will be evaluated according to Standard WHO response criteria, NCI-CTC AE V3.0 and EORTC QLQ-C30 and H&N35 questionnaire.

NCT ID: NCT01540136 Completed - Clinical trials for Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma

Start date: February 2012
Phase: Phase 3
Study type: Interventional

This is a Phase III trial to study the effectiveness of nedaplatin versus cisplatin with IMRT chemoradiotherapy in treating patients with locoregionally advanced nasopharyngeal carcinoma.

NCT ID: NCT01534585 Completed - Clinical trials for Nasopharyngeal Carcinoma

Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

Start date: February 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Nasopharyngeal carcinoma (NPC) is a prevalent disease in southeast of China. Radiation therapy with or without chemotherapy is a standard therapy for nasopharyngeal cancer. Cytotoxic chemotherapy plays an important role in the curative treatment of advanced NPC. However, concurrent chemoradiotherapy increased significantly local and systemic toxic effects, which may preclude many patients from proceeding with combined therapy. The epidermal growth factor receptor(EGFR) gene is amplified in 40% and EGFR protein is overexpressed in over 80% of NPC. EGFR overexpression is also associated with shorter survival following chemoradiotherapy in locoregionally advanced NPC. And some basic researches have proved that EGFR tyrosine kinase inhibitors(TKIs) could increase the radiosensitivity and reduce the epithelial-mesenchymal transition (EMT) in NPC cell line. Moreover, distant metastases has been the major cause of treatment failure in NPC. Icotinib hydrochloride is a novel oral EGFR TKIs with low mammalian toxicity(made in China). But base on toxic effects of Icotinib, it may increase toxic effects about skin and mucosa in combination therapy with Icotinib and Intensity-modulated Radiotherapy (IMRT). The prospective study will assess the tolerability and efficacy of Icotinib combined with IMRT in patients with NPC. This regimen is of great interest and it has potential to alleviate the adverse effects, improve patient compliance and better therapeutic ratio.

NCT ID: NCT01528618 Completed - Clinical trials for Nasopharyngeal Neoplasms

Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma

Start date: February 21, 2012
Phase: Phase 3
Study type: Interventional

The present study will be a randomized, control, multicenter phase III study of recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) treated with Gemcitabine (Gemzar, Lilly) and cisplatin regimen (GP) or 5-Fluorouracil plus cisplatin regimen (FP). The population consists of recurrent or metastatic nasopharyngeal carcinoma (NPC) that failed the radical radiotherapy or chemotherapy-naïve advanced NPC (stage IV). The effectiveness and side effects will be evaluated according to Standard WHO response criteria and NCI-CTC AE V3.0.

NCT ID: NCT01483144 Completed - Clinical trials for Familial Adenomatous Polyposis

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Start date: October 2013
Phase: Phase 3
Study type: Interventional

The purpose of this randomized, double-blind, Phase III trial is to determine if the combination of eflornithine plus sulindac is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of any FAP-related event. This includes: 1) FAP related disease progression indicating the need for excisional intervention involving the colon, rectum, pouch, duodenum and/or 2) clinically important events which includes progression to more advanced duodenal polyposis, cancer or death.

NCT ID: NCT01469429 Completed - Tongue Cancer Clinical Trials

Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.

Start date: September 4, 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized phase I/II trial studies the side effects and best way to give lyophilized black raspberries in preventing oral cancer in high-risk patients previously diagnosed with stage I-IV or in situ head and neck cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of lyophilized black raspberries may prevent oral cancer. Studying samples of oral cavity scrapings, blood, urine, and saliva in the laboratory from patients receiving lyophilized black raspberries may help doctors learn more about changes that occur in DNA and the effect of lyophilized back raspberries on biomarkers.

NCT ID: NCT01462474 Completed - Clinical trials for Locally Advanced Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma

FMTN-I-LNPC
Start date: October 2011
Phase: Phase 1
Study type: Interventional

RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study of mono famitinib has shown that the drug's toxicity is manageable. PURPOSE: This phase I trial is studying the safety and tolerance of concurrent chemoradiotherapy with famitinib for patients with locally advanced nasopharyngeal carcinoma.

NCT ID: NCT01449942 Completed - Clinical trials for Nasopharyngeal Carcinoma

Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma

NPC-DZ
Start date: May 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether an EBV-LMP1 targeted DNAzyme is effective in radiosensitization of nasopharyngeal carcinoma in combination with standard radiation therapy.

NCT ID: NCT01439724 Completed - Clinical trials for Squamous Cell Carcinoma of Oropharynx

Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients

Start date: June 2007
Phase: Phase 3
Study type: Interventional

Oral mucositis remains a limiting factor in in head and neck squamous cell carcinomas patients treated with chemoradiation leading to pain, dysphagia, and weight loss. Low-level laser therapy emerges as a promising, preventive therapy of chemoradiation-induced OM. This study was designed to assess the efficacy of Low Level Laser Therapy (LLLT) in reducing the incidence and/or severity of oral mucositis.